<DOC>
	<DOCNO>NCT01898273</DOCNO>
	<brief_summary>The primary objective trial determine optimal dose imaging time point ( ) I-124-CLR1404 subject newly diagnose recurrent glioma use future trial .</brief_summary>
	<brief_title>Imaging Trial With I-124-CLR1404 Patients With Newly Diagnosed Recurrent Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>newly diagnose glioblastoma recurrent/suspected recurrent glioblastoma schedule undergo clinicallyindicated surgery biopsy ( specific cohort ) ECOG performance status 0 2 ( Appendix C ) 18 year age older initiative mean compliant protocol within geographical proximity make require study visit ability read , understand provide write informed consent initiation study relate procedure ( legal representative ) female childbearing potential must negative pregnancy test within 24 hour enrollment Women childbearing potential men able father child , must agree use effective method contraception ( e.g. , oral contraceptive , doublebarrier method condom diaphragm , intrauterine device , Norplant , DepoProvera ) study 45 day follow last dose study drug . ongoing grade 2 great toxicity due previous therapy . However , tolerable grade 2 adverse ( e.g . neuropathy ) event may allow discretion investigator . follow laboratory abnormality Platelets &lt; 100,000/μL WBC &lt; 3000/μL Hematocrit &lt; 22 % Serum creatinine &gt; 2.5 mg/dL ALT &gt; 1.5 x ULN Bilirubin &gt; 1.5 x ULN ongoing chronic immunosuppressive therapy history hypersensitivity iodine concomitant serious illness organ system dysfunction opinion investigator would either compromise subject safety interfere evaluation safety test drug woman childbearing potential , men able father child , unwilling use medically acceptable method contraception trial pregnancy breastfeed inability comply protocol use investigational drug within 4 week dose ( unless long time period require local regulation investigational agent )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Glioma</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>PET</keyword>
	<keyword>Imaging</keyword>
	<keyword>Radiopharmaceutical</keyword>
	<keyword>Diagnostic</keyword>
</DOC>